Abstract
Introduction:
Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life.
Discussion:
Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Bone Density Conservation Agents / therapeutic use
-
Bone Neoplasms / complications
-
Bone Neoplasms / psychology
-
Bone Neoplasms / secondary*
-
Breast Neoplasms / pathology*
-
Breast Neoplasms / psychology
-
Diphosphonates / therapeutic use
-
Female
-
Fractures, Bone / complications
-
Fractures, Bone / etiology*
-
Fractures, Bone / pathology
-
Fractures, Bone / prevention & control
-
Fractures, Bone / psychology
-
Health Status
-
Humans
-
Imidazoles / therapeutic use
-
Male
-
Pain / etiology*
-
Pain / pathology
-
Prostatic Neoplasms / pathology*
-
Prostatic Neoplasms / psychology
-
Quality of Life* / psychology
-
Zoledronic Acid
Substances
-
Bone Density Conservation Agents
-
Diphosphonates
-
Imidazoles
-
Zoledronic Acid